Gaithersburg, MD, April 27, 2015  – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, announces the appointment of Cold Spring Biotech Corp. as the exclusive authorized distributor of the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System in China, Taiwan, and Hong Kong.

 

“There has been significant interest and demand for the MaxCyte platform in China, Taiwan, and Hong Kong for drug discovery and protein expression applications.” stated Karen Donato, Ph.D., Executive Vice President, Business Development & Marketing at MaxCyte. “MaxCyte is pleased to announce the appointment of Cold Spring Biotech to expand the reach of our transfection technology in this important and growing market. With a proven track record of more than 20 years providing sales and support, Cold Spring Biotech will provide a vital link between MaxCyte and this market.

 

Support for cell therapy applications in China, Taiwan, and Hong Kong will continue to be provided directly by MaxCyte.

 

With offices in Beijing, Shanghai, Guangzhou, and other cities in China, Cold Spring Biotech Corp. distributes instruments, reagents, and consumables for some the biggest manufacturers in the biotechnology market. In addition to its distribution services, CSB provide R&D consultation services on research projects and experimental techniques.

 

Contact information for Cold Spring Biotech can be found on the MaxCyte website.

 

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information visit /

###